 Home > Active Ingredient News > Antitumor Therapy > Nat Commun: Comparison of the efficacy of induction chemotherapy combined with radical radiotherapy and chemotherapy and radiotherapy alone in esophageal squamous cell carcinoma

Nat Commun: Comparison of the efficacy of induction chemotherapy combined with radical radiotherapy and chemotherapy and radiotherapy alone in esophageal squamous cell carcinoma

 Last Update: 2021-08-01
 Source: Internet
 Author: User

Tags

cell death disease

adoptive cell therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Esophageal cancer (EC), the sixth leading cause of cancer-related deaths worldwide, is a fatal disease with a poor prognosis

Although some progress has been made in radiotherapy and chemotherapy regimens in recent years, the prognosis of patients receiving CRT treatment is still not optimistic, and the 3-year overall survival rate (OS) of patients is only 26.

This randomized phase II clinical trial aims to compare the efficacy and safety of induction chemotherapy followed by radical radiochemotherapy (CRT) and CRT alone in ESCC (esophageal squamous cell carcinoma) patients who are not suitable for surgery (number of patients) N=110)

Related research diagram

The results showed that the test did not reach the pre-specified endpoint

Post-mortem analysis showed that the survival rate of patients who responded to induction chemotherapy improved

Kaplan-Meier survival curves of the two treatment groups

All in all, the results of the study revealed that for ESCC patients, adding induction chemotherapy to CRT treatment does not improve the patient's drug response rate or survival rate

The results of the study revealed that for ESCC patients, adding induction chemotherapy to CRT therapy did not improve the patient's drug response rate or survival rate

Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Dacarbazine CAS 4342-03-4 for Scientific Research Chemical Reagents Use only

CAS No.: 4342-03-4

Pharmacy Grade

$4-5/G FOB

Lapatinib 99% white powder CAS231277-92-2 bulk Lapatinib

CAS No.: 231277-92-2

Pharmacy Grade

$88-98/KG FOB

Mitomycin C

CAS No.: 50-07-7

Industrial Grade

$0.1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.